Trials / Completed
CompletedNCT00003061
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma
Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- All
- Age
- 16 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate and cytarabine plus radiation therapy in treating patients who have primary CNS lymphoma.
Detailed description
OBJECTIVES: I. Determine the efficacy of methotrexate and cytarabine chemotherapy in combination with whole-brain radiation therapy for patients with non-AIDS related primary central nervous system lymphoma. II. Assess the response rate and safety of this chemotherapy regimen. OUTLINE: Patients receive the first course of chemotherapy as soon as possible after diagnosis and staging. Methotrexate (MTX) IV is administered over 40-60 minutes on days 1 and 15. Cytarabine (AraC) is administered intrathecally on days 1 and 15. The second course of chemotherapy begins on day 29 or after bone marrow recovery. Radiation therapy begins no later than 3 weeks after completing chemotherapy. Patients are followed until death. PROJECTED ACCRUAL: A maximum of 50 patients will be accrued.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cytarabine | |
| DRUG | methotrexate | |
| RADIATION | radiation therapy |
Timeline
- Start date
- 1997-07-01
- Primary completion
- 2002-03-01
- First posted
- 2004-04-14
- Last updated
- 2012-07-02
Locations
7 sites across 3 countries: Belgium, France, Netherlands
Source: ClinicalTrials.gov record NCT00003061. Inclusion in this directory is not an endorsement.